Calendar Year 1990

Initial Public Offering

Calendar Year 1991

Initial Launch of Pharmaceutical Products

Established Dermatological Sales Force

Acquired ESOTERICA® from SmithKline Beecham

Calendar Year 1992

Calendar Year 1993

Introduced DYNACIN™

Calendar Year 1994

No Data Available

Calendar Year 1995

Relocated to Phoenix, AZ

Launched TRIAZ™

Calendar Year 1996

1 for 14 Reverse Stock Split

Introduced Dye-Free DYNACIN™

3 for 2 Stock Split

Calendar Year 1997

3 for 2 Stock Split

Completed Public Offering Raising More Than $95 Million

Acquired LIDEX® and SYNALAR® from Syntex

Collaboration with Abbott Laboratories

Received Patent for TRIAZ™

Acquired GenDerm Corporation

Calendar Year 1998

Completed Public Offering Raising More Than $210 Million

Launched LUSTRA®

Listed on NYSE

Acquired LOPROX™ and TOPICORT® from Aventis (HMR)

Calendar Year 1999

Began Promotion to Podiatrists

3 for 2 Stock Split

Sold and Licensed Products to Bioglan

Acquired Ucyclyd Pharma Inc.

Launched LUSTRA-AF®

Launched DYNACIN™ 75 mg

Received Patent on LUSTRA® Composition

Acquired VECTRIN Product Line from Warner Chilcott

Chairman and CEO Selected to Serve on NYSE Advisory Committee

Launched LOPROX™ Gel

Calendar Year 2000

Established Stock Repurchase Program

Launched OVIDE®

Relocated to Scottsdale, AZ

Calendar Year 2001

Launched PLEXION™ and PLEXION™ TS

Collaboration with Corixa

Announced PVAC™ Phase II Trial Preliminary Results

Licensed OMNICEF® from Abbott Laboratories for Dermatology and Podiatry in U.S.

Launched ALUSTRA®

Completed Merger with Ascent Pediatrics

Began Promotion to Pediatricians

Calendar Year 2002

Launched PLEXION SCT™

Issued $350 Million Contingent Convertible Senior Notes Due 2032

Strategic Alliance with aaiPharma

License and Development Agreement with Dow Pharmaceutical Sciences

Calendar Year 2003

Launched LOPROX™ TS

Licensed Four Branded Products to Taro

Acquired Exclusive License to RESTYLANE™ Family of Products

Launched LOPROX™ Shampoo

Launched DYNACIN™ Tablets

Declared First Dividend

Launched TRIAZ™ Pads

Completed Exchange Offer for Contingent Convertible Senior Notes Due 2033

Discontinued PVAC™ Development

Calendar Year 2004

2 for 1 Stock Split

Launched RESTYLANE™

Licensed ORAPRED® to BioMarin

Licensed RESTYLANE^™ and SubQ from Q-Med AB

Licensed LUSTRA® Family of Products to Taro

Launched PLEXION™ Cleansing Cloths

Licensed Proprietary Peptide Technology from Ansata Therapeutics

Calendar Year 2005

Supermodel Frederique van der Wal Signed on as the New Face of RESTYLANE^™

FDA Approved NDA for VANOS^™

FDA Approved AMMONUL^™

Launched Restylane Rewards^℠

Announced Agreement to Merge with Inamed

Board Unanimously Rejected Mentor Proposal

Requested That Inamed Recommend Rejection of Allergan Exchange Offer

Terminated Merger Agreement with Inamed; Received $90 Million Termination Fee

Calendar Year 2006

FDA Approved Broader Indication for VANOS^™

Ipsen Granted Medicis Rights to Distribute and Promote RELOXIN^™ for aesthetic use in the U.S.

Two Patents Issued for LOPROX^™ Gel

FDA Approved SOLODYN^™ -- minocycline HCl, USP -- Extended Release Tablets

Launched Search for the "Hottest Mom in America^™"

Medicis and Dow Pharmaceutical Sciences announce FDA Approval of ZIANA^™ (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel

Calendar Year 2007

Launched ZIANA^™

Launched PERLANE^™

Launched TV Ad Campaign for RESTYLANE^™

Announced Strategic Collaboration with Hyperion Therapeutics

Announced Share Repurchase Program up to $200 Million

BLA for RELOXIN^™ in Aesthetics Submitted to FDA

Announced Strategic Collaboration with Revance Therapeutics

Calendar Year 2008

Increased Cash Dividend to $0.04 Per Share

BLA for RELOXIN^™ in Aesthetics Submitted to FDA by Ipsen

Announced Organizational Changes

BLA for RELOXIN^™ in Aesthetics Accepted by FDA

Completed Acquisition of LipoSonix, Inc.

FDA Approved PMA Supplement for RESTYLANE^™

Announced R&D Collaboration and Settlement with Impax

Calendar Year 2009

Introduced TRIAZ^™ 6% Foaming Cloths

Announced Notice of Allowance for SOLODYN^™ 90mg

Announced New Notice of Allowance for SOLODYN^™ 90mg

FDA Approved DYSPORT™ (abobotulinumtoxinA) for Therapeutic and Aesthetic Uses

Announced New Patents for SOLODYN^™ 90mg

Launched DYSPORT™

Announced Approval of New Strengths of SOLODYN^™

Introduced TRIAZ^™ 3% Foaming Cloths

Announced Notice of Allowance for SOLODYN^™ Patent

Calendar Year 2010

Announced Approval for RESTYLANE^™ and PERLANE^™ with Lidocaine

Launched RESTYLANE-L™ and PERLANE-L™

Announced DYSPORT™ Challenge: Love It or Leave It

Increased Cash Dividend to $0.06 Per Share

Introduced TRIAZ^™ 9% Foaming Cloths

Extended Popular DYSPORT™ Challenge by One Month

Extended DYSPORT^™ Challenge: Over 90% Chose "Love It"

Launched RESTYLANE-L™ and PERLANE-L™ in Canada

Announced Organizational Changes

Announced DYSPORT^™ Challenge Surpasses 100,000 Registrants

Announced Approval of Additional Strengths of SOLODYN^™

Calendar Year 2011

Medicis and Anacor Enter Into Research and Development Collaboration for the Treatment of Acne

Medicis Named to "World's Most Ethical Companies" List

FDA Panel Recommends Lip Indication for Medicis' RESTYLANE^®

Medicis Announces FDA Clearance of LIPOSONIX^® System

Medicis and Solta Announce Agreement for LIPOSONIX^®

FDA Approves Lip Indication for Medicis' Restylane^®

Medicis and Solta Announce Close of Agreement for LipoSonix^®

Medicis Wins Auction for Graceway Pharmaceuticals

Medicis Announces Close of Graceway Acquisition